StageUnattributed VC - III | Alive
Last Raised$18.33M | 16 yrs ago
About BioSante Pharmaceuticals
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's key products are LibiGel® (testosterone gel) in Phase III clinical development under an SPA, to treat female sexual dysfunction, and Elestrin (estradiol gel), FDA approved to treat hot flashes in menopausal women. The current market for testosterone and estrogen products is approximately $2.5 billion dollars in the U.S. alone, with estimates for female sexual dysfunction potentially adding $2.0 - $4.0 billion, and the current market for hormonal contraception is approximately $3.0 billion.
Missing: BioSante Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: BioSante Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing BioSante Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
BioSante Pharmaceuticals is included in 2 Expert Collections, including Women's Health & Wellness.
Women's Health & Wellness
Startups focused on providing products and services catering to women's health and wellbeing.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
BioSante Pharmaceuticals Patents
BioSante Pharmaceuticals has filed 10 patents.
Clusters of differentiation, Immune system, Monoclonal antibodies, Radiation therapy, Oncology
Clusters of differentiation, Immune system, Monoclonal antibodies, Radiation therapy, Oncology
Latest BioSante Pharmaceuticals News
Jun 23, 2021
| Analysis and Forecast Report with Key Players- Merck & co., BioSante Pharmaceuticals and Amgen, QuatRx Pharmaceuticals, Noven Pharmaceuticals. Estrogen and progesterone are female hormones that play important roles in a woman’s body. Falling levels cause a range of physical and emotional symptoms, including hot flushes, mood swings and vaginal dryness. The aim of hormone replacement therapy is to restore female hormone levels, allowing the body to function normally again. Impact of COVID-19 on the Healthcare Industry The COVID-19 pandemic has causedsevere impacts on the global economy at various levels and which can be seen onthe Healthcare industry as well. The thriving market of health care researchand development is expected to exhibit a steep decline in the sales during thelockdown period owing to the shutdown of the manufacturing units, acuteshortage in the supply of raw materials and absence of potential manpower. Itcan be deduced from the current situations brought about by the pandemic thatthe production, and supply chain activities have experienced minor hurdles.However, the market is projected to gradually recover post-COVID-19, which willpresent attractive opportunities for sales across various regions of the worldin the following years. Future Market Insights (FMI) adopteda multidisciplinary approach during the pandemic-era to focus on the growth anddevelopment of the HormoneReplacement Therapy Market . Thestudy features insights on the current growth dynamics and the major revenuereforms prevailing in the market as along with the key takeaways over theforecast. The team of analysts at Future MarketInsights are focussing on research and market study to produce different HormoneReplacement Therapy Market forecasts and predictions at both national andinternational levels. They have considered several leads of informationpertaining to the industry like market figures and merger estimations to assessand produce reliable and informative insights on the Hormone ReplacementTherapy Market. To remain ‘ahead’ of your competitors, Ask aQuestion >> https://www.futuremarketinsights.com/ask-question/rep-gb-3871 Key Players The writer will create content on thegeneral strategies of market players. And then will write the key players inthe market are: Bayer AG, Pfizer, Merck & co., BioSante Pharmaceuticals andAmgen, QuatRx Pharmaceuticals, Noven Pharmaceuticals Segmentation The report provides insights on the important highlights and currenttrends prevailing in the market. This helps the readers to gain a deeperunderstanding and form an unbiased opinion on the market. Numeroussegmentations have been provided for this market based on: Based on TherapyType, Fullin-depth analysis of the parent market The analysts at FMI are dedicated toprovide insights after extensive research and study. The study also includesestimations, projections and evaluation of the market dynamics. Importantchanges in market dynamics The report has beencreated after detailed and exhaustive studies by the analysts at FMI takingseveral factors into consideration like monetary, ecological, social,mechanical, and political status of a particular demography. They study the keydata to assess the revenue and production of manufacturers across variousregions. The report also covers an in-depth analysis ofthe key changes in market dynamics in the recent past and the near future. Segmentationdetails of the market Emerging segments and regional markets Queries Solved What is the size of the overall HormoneReplacement Therapy Market in the Healthcare Industry and its segments? What are the key segments andsub-segments in the market? What are the key drivers, restraints,opportunities, and challenges of the Hormone Replacement Therapy Market in theHealthcare Industry, and how they are expected to impact the market? What are the attractive investmentopportunities within the Hormone Replacement Therapy Market in the HealthcareIndustry? What is the Hormone ReplacementTherapy Market in the Healthcare Industry size at the regional andcountry-level? What are the key market playersfocusing on? What are the strategies for growthadopted by the key players in Hormone Replacement Therapy Market in theHealthcare Industry? What are the recent trends in HormoneReplacement Therapy Market in the Healthcare Industry? (M&A, partnerships,new product developments, expansions)? What are the challenges to the HormoneReplacement Therapy Market in the growth of the Healthcare Industry? What are the key market trendsimpacting the growth of the Hormone Replacement Therapy Market in theHealthcare Industry? To receive extensive list of importantregions, ask for TOC here >> https://www.futuremarketinsights.com/toc/rep-gb-3871 Table of Content MarketBackground Reasons to Buythe report We provide authentic and detailed ananalysis on various market trends to enable businesses to make informed andbeneficial decisions to attain competitive edge over key players. Our analysts provide detailed marketsegmentation along with meaningful insights and extensive reports that othercompanies fail to include. The report includes accurate analysisof the market and the current developing trends affecting the growth. FMI speaks tostakeholders across the spectrum, including C-level executives, distributors,product manufacturers, industry experts. This ensures that the data collected is fromhighly reliable sources. Explore Wide-ranging Coverage of FMI’s HealthcareLandscape Transradial Closure Devices Market – According to Future Market Insights (FMI), the demand from hospitals,independent catheterization centers, and healthcare clinics will continuerising. Spurred by this, the global transradial closure devices market is setto grow by 6.5% CAGR during the forecast period from the year 2020 to 2030. In Vitro FertilizationBanking Services Market – The in vitro fertilization banking services market,despite undergoing a temporary period of lull due to COVID-19 outbreak, islikely to have an impressive growth trajectory between 2020 and 2030. Cryopreservationfor In-vitro Fertilization (IVF) Market – According to analysis by Future Market Insights (FMI), cryopreservationfor IVF market surpassed a valuation of US$ 339 million in 2019. Themarket is set to reflect an impressive 10.2% CAGR through 2030. About FMI Future Market Insights (FMI) is a leading provider of marketintelligence and consulting services, serving clients in over 150countries. FMI isheadquartered in Dubai, the global financial capital, and has delivery centersin the U.S. and India. FMI’s latest marketresearch reports and industry analysis help businesses navigatechallenges and make critical decisions with confidence and clarity amidstbreakneck competition. Our customized and syndicated market research reportsdeliver actionable insights that drive sustainable growth. A team of expert-ledanalysts at FMI continuously tracks emerging trends and events in a broad rangeof industries to ensure that our clients prepare for the evolving needs oftheir consumers. ContactUs
BioSante Pharmaceuticals Frequently Asked Questions (FAQ)
When was BioSante Pharmaceuticals founded?
BioSante Pharmaceuticals was founded in 1996.
Where is BioSante Pharmaceuticals's headquarters?
BioSante Pharmaceuticals's headquarters is located at 111 Barclay Boulevard, Lincolnshire.
What is BioSante Pharmaceuticals's latest funding round?
BioSante Pharmaceuticals's latest funding round is Unattributed VC - III.
How much did BioSante Pharmaceuticals raise?
BioSante Pharmaceuticals raised a total of $36.26M.
Who are the investors of BioSante Pharmaceuticals?
Investors of BioSante Pharmaceuticals include Sheffield Asset Management, Paramount BioCapital Asset Management, Bristol Capital Advisors, Cantara, Diamond Asset Management Llc and 30 more.
Who are BioSante Pharmaceuticals's competitors?
Competitors of BioSante Pharmaceuticals include Oligomerix, Clarus Therapeutics, Portola Pharmaceuticals, Keryx Biopharmaceuticals, ARIAD Pharmaceuticals and 12 more.
Compare BioSante Pharmaceuticals to Competitors
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.
BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.
Oraceuticals uses biotechnologies to develop drugs that advance oral treatment and improve oral health. Focuses on producing bioactive molecules that target chronic oral infections and control inflammation.
Biolog specializes in microbial identification, phenotypic cell profiling, and metabolic fingerprinting for microbial and mammalian cells. The company’s products enable the identification of thousands of species of bacteria, yeast, and fungi, as well as the characterization of human cells and mitochondria. Biolog's products are available worldwide, either directly from the company or through its extensive network of international distributors. The company was founded in 1984 and is based in Hayward, California.
Limerick BioPharma is developing compounds that per the company when used adjunctively with both marketed and investigational drugs improve drug side effect profiles and clinical outcomes. By activating cellular transport pumps to redistribute drugs away from organs and tissues where they have adverse effects, the company's compounds aim to minimize toxic side effects at non-targeted vulnerable organs and tissues while maintaining or enhancing a drug's desired effects. Per the company, Limerick's pipeline molecules are applicable to a broad range of therapeutic drug classes including immunosuppressants, opioids, immunomodulators, selective estrogens receptor modulators, and psychotropics. In the monotherapy setting, Limerick is developing novel compounds that target the treatment of metabolic diseases such as hypercholesteremia and hyperglycemia via a mechanism related to reverse cholesterol transport.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.